Case Report

Extradural malignant melanotic schwannoma of the spine: Case report and an up to date systematic review of the literature

Georgios Solomou a,*, Adikarige Haritha Dulanka Silva b, Adrianna Wong c, Ute Pohl d, Nikolaos Tzerakis e,**

a School of Medicine, Keele University, Staffordshire, UK Hospital Campus, Newcastle Road, Stoke-on-Trent ST4 6QG, UK
b Paediatric Neurosurgery Fellow, Department of Neurosurgery, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK
c School of Medicine, Keele University, Staffordshire, UK Hospital Campus, Newcastle Road, Stoke-on-Trent ST4 6QG, UK
d Consultant Neuropathologist, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston Birmingham, B15 2GW, UK
e Consultant Neurosurgeon, University Hospital of North Midlands, Stoke on Trent, ST4 6QG, UK

ARTICLE INFO

Keywords:
Extradural
Melanotic
Malignant
Metastatic
Schwannoma

ABSTRACT

Background: Melanotic schwannoma is a rare variant of schwannoma. Extradural melanotic schwannoma originates in the vicinity of nerve roots mimicking other intervertebral disc disorders. Therefore, T1 and T2-weighted MRI sequences become an essential tool for diagnosis. Aside from case reports, no large studies exist to provide consensus on the signal intensities in T1 and T2-weighted MR imaging. Moreover, no clear evidence is available to delineate prognosis. Here, a case report is presented together with a subsequent systematic review of the literature regarding this rare entity.

Case description: A 45-year-old female presented with a one-year history of insidious onset of neck pain and paraesthesia. Magnetic resonance imaging confirmed an extradural lesion along the C6 nerve root with T1-weighted hyperintensity and T2-weighted hypointensity. Despite two surgical decompressions and adjuvant immunotherapy, the patient unfortunately passed away due to metastatic progression.

Discussion: According to the systematic review conducted, in over half of the cases of extradural melanotic schwannoma, there is local recurrence and/or distal metastasis. Moreover, in 64.7% and 70.6% of the cases, the T1-weighted image of the lesion appears hyperintense and T2-weighted hypointense, respectively. It is a highly aggressive variant of schwannoma, one of the most commonly observed extradural tumours presenting to neurosurgical practice.

Conclusion: Our results highlight that specific T1 and T2-weighted imaging findings can provide valuable information, enabling early suspicion, influencing the surgical aims and strategy and the timely commencement of relevant immunotherapy. Considering the poor prognosis, early adjuvant therapy with other modalities should be considered.

1. Introduction

Schwannomas are solitary, encapsulated and slow-growing neoplasms composed of Schwann cells constituting the nerve sheath [1]. Melanotic schwannoma (MeS) or melanocytic schwannoma, initially described by Millar in 1932 [2], is a rare variant composed of neoplastic Schwann cells that produce melanin and account for less than 1% of primary peripheral nerve sheath tumours [1]. It is hypothesized that Schwann cells are capable of synthesizing melanin, owing to a common progenitor of both Schwann cells and melanocytes being migrating neural crest cells [3]. Macroscopically, they appear black, brown or dark blue in colour, whereas under light microscopy, there is evidence of heavy melanin deposition, spindle morphology, nuclear pleomorphism and low mitotic rate with or without psammoma bodies [4,5]. To date, approximately 200 cases of MeS have been described in the literature, predominantly as case reports, but also some small case series. Posterior

* Corresponding author.  
** Corresponding author.  
E-mail addresses: w4r99@students.keele.ac.uk (G. Solomou), nikolaos.tzerakis@uhnm.nhs.uk (N. Tzerakis).

https://doi.org/10.1016/j.amsu.2020.10.003
Received 7 August 2020; Received in revised form 25 September 2020; Accepted 4 October 2020
Available online 7 October 2020
2049-0801/Crown Copyright © 2020 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license
nerve roots represent the most frequently involved site (30.5%) [6], but MeS affecting the spinal cord, sympathetic chain, cranial nerve roots, peripheral nerves and the gastrointestinal tract [7–12] have also been documented. It is generally accepted that MeS can be divided into psammomatous and non-psammomatous [13–15] subtypes. In 1990, Carney described the psammomatous MeS as a distinct clinicopathologic entity and proposed it be considered as part of the Carney complex in conjunction with the presence of cutaneous lesions, endocrine tumours and cardiac myxoma [13]. A Mendelian dominant hereditary pattern was then defined as being responsible for the clinical phenotype [16]. Extramedullary MeS presents in similar fashion to other extramedullary spinal tumours. Originating in the vicinity of the spinal nerve roots, it often leads to compression within and narrowing of the intervertebral foramen, leading to the manifestations of radicular pain, back pain, dysesthesias and progressive sensory and motor deficits. The non-specific combination of radicular pain and back pain can often lead to the clinical misdiagnosis of an intervertebral disc disorder. As the tumour grows, it leads to the progression of motor and sensory signs with Magnetic Resonance Imaging (MRI) guided assessment, an important diagnostic tool [17].

Until 1998, the MRI characteristics of MeS of the spine had not been described. Bendzus et al. originally described the lesion to appear hyperintense in T1 and hypointense in T2 [18]. There have been no extensive reviews focusing on the imaging of MeS, although it has been globally accepted that it has a characteristic hyperintensity on T1-weighted sequence and hypointensity on T2-weighted sequence [19]. Clinically, several studies have commented on the malignant and metastatic potential of MeS, however, with heterogeneous outcomes [12,51,57]. We describe and discuss a case of rare fulminant MeS with distal and local metastases, and provide a systematic review of both imaging as well as prognostic outcomes regarding MeS, including highlighting its metastatic potential.

2. Case report

2.1. History

A 45-year-old female patient of white ethnic background was referred to the neurosurgical service by the spinal physiotherapy department. She presented with a one-year history of insidious neck pain radiating to the shoulder girdle, left arm and thumb, with associated paraesthesia in the same distribution. The pain was worse on resting and relieved by non-steroidal anti-inflammatory drugs (NSAIDs). An initial diagnosis of C6 radiculopathy was made and, given the failure of conservative management, she was offered a contrast-enhanced MRI. The only relevant past medical history was that of hiatus hernia and thyroid adenoma for which she had a partial thyroidectomy 10 years previously, with levothyroxine as the only regular medication. No family history of malignancy was found.

2.2. Radiological findings

Cervical spine imaging revealed a dumbbell-shaped lesion along the C6 nerve root, with both intradural and extradural components. The central portion of the extradural component, in particular, demonstrated T2 hypointensity on most sequences, while the peripheral portions enhanced homogeneously ('target' sign, consistent with a peripheral nerve sheath tumour [usually suggestive of neurofibroma, but also seen in schwannomas and malignant peripheral nerve sheath tumours]) [20]. The overall appearances were consistent with schwannoma (Fig. 1).

2.3. Surgical approach/management

Following discussion at the neuro-oncological multi-disciplinary team (MDT) meeting, a recommendation for surgical excision was made. A C5/6 left hemilaminectomy was performed under intra-operative neurophysiological monitoring (IONM). Post-operatively, the patient showed improvement of symptoms in the left arm.

2.4. Histopathological findings

Histology revealed a heavily pigmented spindle cell neoplasm, arranged in solid sheets and fascicles, with focal epithelioid differentiation and several well-defined areas of necrosis. The individual tumour cells displayed nuclear pleomorphism with prominent nucleolation and well-defined basophilic cytoplasm with finely granular brown pigment consistent with neuromelanin. Mitoses amounted to 3/single high power field (×40 objective). Psammoma bodies were absent. Immunohistochemistry showed a nuclear labelling index for the proliferation marker ki-67 of up to 25%, and strong staining for S100, MelanA and HMB45, while pancytokeratin CK AE1/3 was negative. Histochromy for reticulin demonstrated predominantly pericellular collagen staining in the tumour, while focal loss of pericellular reticulin deposition was noted in some areas. A diagnosis of ‘malignant melanotic spindle cell neoplasm, consistent with malignant melanotic schwannoma’, based on the anaplastic histological features in this biopsy, was confirmed.

The latest edition of the WHO classification of tumours of the central nervous systems (2016) has not yet assigned a grade for this variant, but its aggressive behaviour reported in the literature suggests a grade of at least WHO III. Genetic analysis was negative for BRAF V600 mutation.
and PD-L1 expression was absent. Further genetic studies were not undertaken. Although the histology was most in keeping with a malignant melanotic schwannoma, at MDT, a dermatological review was recommended to rule out the possibility of metastatic malignant melanoma.

2.5. Further management

In light of histology and MDT discussion, the patient was referred to dermatology for an urgent review and staging computerised tomography (CT) scan of the chest, abdomen and pelvis.

CT at the time showed no evidence of peripheral metastases, whilst dermatology review revealed a 6mm asymmetrical ugly duckling naevus in the skin over the left knee [21]. There was no clinical evidence of Carney’s complex. The skin lesion was then biopsied, which was diagnosed as a pT1a AJCC stage group 1a melanoma (Fig. 2). Wide local excision of the skin lesion was advised to ensure clear margins.

Re-exploration to achieve gross total resection of the extradural portion of the spinal tumour, as well as amputation of the C6 nerve root for local control was recommended. Pre-operatively, left vertebral artery occlusion was performed to reduce tumour vascularity and optimise the feasibility of achieving gross total resection. An anterior cervical approach was attempted but owing to significant tumour adherence, a subsequent revision posterior approach was required to accomplish gross total resection of the lesion and amputation of the nerve root.

2.6. Post-operative outcomes

After surgery, the patient experienced transient dysphagia due to post-surgical cervical haematoma, which responded well to conservative management with dexamethasone. Post-operative imaging confirmed excision of the majority of the residual enhancing lesion, with only a small residuum remaining. Adjuvant radiotherapy was commenced two months after surgery.

Three months following the completion of radiotherapy, the patient developed right-sided hip pain and subsequent imaging revealed a large metastasis in the right femoral neck that resulted in a pathological intracapsular fracture of the right femoral neck. A right hip hemi-arthroplasty was thus carried out. In light of the bone metastasis, another staging CT was performed, revealing multiple lung metastases and possible liver metastasis. The patient was subsequently started on combination immunotherapy involving Nivolumab, an antibody against programmed death 1 (PD-1) receptor, Ipilimumab, an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as well as Denosumab, Receptor activator of nuclear factor kappa-B (RANK) ligand-specific antibody [22,23].

Unfortunately, the patient’s disease progressed despite treatment. She was readmitted to the hospital one month following the start of immunotherapy for bilateral pleural effusions, as well as pneumonia. Due to a rapid decline in her functional and performance status, palliative care and support was initiated. The patient passed away shortly after, within 15 months of diagnosis. The case report was written in retrospect and as such the patient’s perspective was not feasible to be included.

2.7. Review of the literature and discussion

A systematic literature review was conducted across known databases, PubMed, EMBASE, Medline and reviewed the reported cases of extramedullary spinal MeS to date. A total of 65 cases were identified with the diagnosis of MeS (Table 1) across 46 published papers.

In 61/65 (93.8%) cases, the gender was available, of which 33/61 (54.1%) were male, and 28/61 (45.9%) were female — patients with extramedullary MeS most commonly presented between 30 and 40 years of age (Fig. 3).

In 37/65 of the cases, information regarding metastasis was available. In 19/37 (51.4%) cases, evidence of metastasis or local recurrence was found, of which 9/37 (24.3%) had both distal metastasis and local recurrence, 5/37 (13.5%) had local recurrence in isolation, and 5/37 (13.5%) had distal metastasis in isolation (Fig. 4). In 18/37 (48.6%), no evidence of recurrence or metastases were noted. Notably, the follow-up time across studies was highly variable, ranging from a few months up to two years.
Table 1
Shows the number of MeS cases found in the literature. Level of lesion, age, gender, metastatic potential and T1-weighted and T2-weighted MRI imaging findings.

| Level       | Gender | Age | Reference | Metastasis | Region         | MRI T1          | MRI T2          |
|-------------|--------|-----|-----------|------------|----------------|-----------------|-----------------|
| **Cervical**|        |     |           |            |                |                 |                 |
| C1          | M      | 34  | [6]       | yes        | Local and distal| –               | –               |
| C1          | –      | –   | [19]      | –          | –              | –               | –               |
| C1          | M      | 54  | [24]      | no         | N/A            | hyperintense    | hypointense     |
| C2          | F      | 30  | [17]      | yes        | local          | hyperintense    |                 |
| C2-3        | F      | 66  | [25]      | –          | –              | –               | –               |
| C3-3        | F      | 35  | [12]      | yes        | Local and distal| –               | –               |
| C4          | M      | 36  | [26]      | yes        | distal         |                 |                 |
| C4          | –      | –   | [19]      | –          | –              | –               | –               |
| C4-5        | F      | 32  | [27]      | yes        | distal         | hyperintense    | hypointense     |
| C5-6        | F      | 53  | [28]      | no         | N/A            | isoointense     | hyperintense    |
| C6          | F      | 26  | [29]      | no         | N/A            |                 |                 |
| C6-7        | M      | 27  | [30]      | yes        | local          |                 |                 |
| C7          | M      | 64  | [10]      | yes        | Local and distal| hyperintense    | hypointense     |
| C8          | F      | 49  | [31]      | –          | –              | –               | –               |
| C8          | F      | 49  | [32]      | no         | N/A            |                 |                 |
| **Thoracic**|        |     |           |            |                |                 |                 |
| T1-T1       | F      | 17  | [18]      | no         | N/A            | hyperintense    | hypointense     |
| T2          | F      | 45  | [33]      | –          | –              | –               | –               |
| T2          | F      | 12  | [31]      | –          | –              | –               | –               |
| T2-4        | M      | 47  | [34]      | no         | N/A            | hyperintense    | hypointense     |
| T3          | F      | 40  | [35]      | no         | N/A            |                 |                 |
| T5          | M      | 38  | [36]      | no         | N/A            |                 |                 |
| T6-7        | M      | 40  | [37]      | –          | –              | –               | –               |
| T6          | M      | 34  | [6]       | yes        | distal         |                 | –               |
| T6-8        | F      | 65  | [38]      | yes        | local          | hyperintense    | –               |
| T7          | M      | 59  | [39]      | yes        | local          |                 |                 |
| T7          | M      | 25  | [40]      | yes        | Local and distal| hyperintense    | hypointense     |
| T7          | M      | 61  | [41]      | –          | –              | –               | –               |
| T8-12       | M      | 67  | [42]      | no         | N/A            | hyperintense    | hypointense     |
| T9          | M      | 43  | [12]      | –          | –              | –               | –               |
| T9-10       | M      | 53  | [8]       | no         | N/A            | hyperintense    | hypointense     |
| T10         | F      | 58  | [43]      | –          | –              | –               | –               |
| T12-L1      | F      | 17  | [44]      | no         | N/A            |                 | –               |
| T12-L2      | –      | –   | [45]      | –          | –              | –               | –               |
| **Lumbar**  |        |     |           |            |                |                 |                 |
| L1          | F      | 23  | [41]      | –          | –              | –               | –               |
| L1          | M      | 32  | [12]      | no         | N/A            |                 | –               |
| L1-2        | M      | 43  | [46]      | no         | N/A            | hyperintense    | hyperintense    |
| L1-2        | M      | 22  | [47]      | no         | N/A            | hyperintense    | hyperintense    |
| L1-2        | F      | 75  | [19]      | –          | –              | –               | –               |
| L2          | M      | 42  | [19]      | –          | –              | –               | –               |
| L2          | M      | 37  | [48]      | –          | –              | –               | –               |
| L1-5        | F      | 35  | [19]      | –          | –              | –               | –               |
| L3          | F      | 70  | [49]      | –          | –              | –               | –               |
| L3          | F      | 46  | [50]      | yes        | local          | hyperintense    | hyperintense    |
| L3-5        | F      | 25  | [6]       | yes        | Local and distal| –               | –               |
| L4          | M      | 59  | [51]      | yes        | Local and distal| –               | –               |
| L4          | F      | 40  | [12]      | yes        | Distal and local| –               | –               |
| L4-5        | M      | 60  | [49]      | –          | –              | hyperintense    | hypointense     |
| L5          | M      | 27  | [6]       | yes        | distal         |                 | –               |
| L5-51       | M      | 28  | [52]      | yes        | Local and distal| hyperintense    | –               |
| L5-51       | M      | 36  | [53]      | –          | –              | –               | –               |
| L5-51       | M      | 33  | [38]      | yes        | Local and distal| –               | –               |
| L5-51       | F      | 36  | [50]      | yes        | Local          | hyperintense    | mixed           |
| **Sacral**  |        |     |           |            |                |                 |                 |
| S1          | F      | 26  | [54]      | no         | N/A            | –               | –               |
| S1          | M      | 36  | [51]      | –          | –              | –               | –               |
| S1          | F      | 63  | [18]      | –          | –              | –               | –               |
| S1          | F      | 41  | [6]       | no         | N/A            | –               | –               |
| **Level Unknown** | | | | | | | |
| N/A         | M      | 46  | [55]      | no         | N/A            | –               | –               |
| N/A         | –      | –   | [8]       | no         | N/A            | –               | –               |
| N/A         | F      | 56  | [56]      | –          | –              | –               | –               |
| N/A         | M      | 58  | [56]      | –          | –              | –               | –               |
| N/A         | M      | 32  | [57]      | –          | –              | –               | –               |
| N/A         | M      | 35  | [19]      | –          | –              | –               | –               |
| N/A         | M      | 28  | [58]      | –          | –              | mixed           | hypointense     |
| N/A         | M      | 57  | [58]      | –          | –              | mixed           | hypointense     |
| N/A         | F      | 41  | [58]      | –          | –              | mixed           | hypointense     |

*No access to full article or the article was not available in English.*
common thoughts regarding the histological classification, incidence and management of extramedullary MeS. According to the recent literature [34, 50], there are two topics, which are still under discussion and subject to further evaluation regarding MeS. These are the T1- and T2-weighted MRI findings of MeS and the future prognosis regarding local recurrence and distant metastasis. According to our knowledge, there are no attempts to capture and summarise the radiological and prognostic evidence to date. Here, we endeavour to discuss our results in the context of the literature.

The literature review conducted, revealed similar age distribution to other studies, with 30–40 years of age being the most common age of presentation [6, 7]. Moreover, the gender distribution revealed a 1.2:1 male to female ratio similar to other studies focusing on MeS [6, 7, 17].

It is widely accepted that MeS exhibit T1-weighted hyperintensity and T2-weighted hypointensity. On the contrary, schwannomas exhibit hypointensity on T1 and hyperintensity on T2. The review of 65 cases conducted, revealed that 64.7% of cases of MeS appear hyperintense, and 70.6% of cases appear hypointense in T1- and T2-weighted MRI sequences, respectively. Melanin exhibits paramagnetic effects, resulting in stable free radicals [59-61]. In essence, melanin protons have shorter T1 & T2 relaxation times. Therefore they quickly recover after an MRI pulse, and are able to appear brighter, leading to a hyperintense and hypointense T1 and T2 signals, respectively. The concentration of melanin and the density of the tumour are however not always consistent.

Notably, Liu et al. showed that 95% of primary spinal melanomas showed T1 and T2-weighted hyper and hypointensity, respectively [62]. Since higher melanin concentration was associated with higher T1-weighted signal intensities and lower signal intensities on T2-weighed images [61], tumours which have melanocytes as their cell origin might have a greater concentration of melanin compared to MeS. Thus, having even slower relaxation times and being less affected by the surrounding environment leads to higher specificity of T1 and T2 hyper- and hypointense signals, respectively.

Moreover, haemorrhage is common in CNS tumours [63]. Deoxy-haemoglobin and all iron-containing haeme groups exhibit paramagnetic effects. Timing of bleeding is also important: acute haemorrhage shows similar MRI findings to MeS (hyperintense T1 and hypointense T2), whereas subacute haematoma might show hyper-intense signal on T1 and hypo-intense T2-weighted images as well [64]. Therefore, melanin concentration and the extent and timing of haemorrhage are all of great significance to the MRI findings.

The identification of a coincidental cutaneous melanoma in our patient raised the question whether the skin lesion and the spinal tumour were causally related and whether the latter represented a metastatic malignant melanoma. However, the skin lesion was in an early, micro-invasive stage with very low metastatic potential. In addition, both radiological and histological features of the spinal tumour strongly favoured melanotic schwannoma over melanoma, and paraspinal location of metastatic melanoma is rare.

With regards to prognosis, an early literature review by Vallat-Decouvelaere [6] identified a metastatic disease in up to 26% of patients with MeS. More recently, Zhan et al. demonstrated that MeS could metastasize in 9.1% of the cases and recurred locally in 18.2% of the cases after resection [12]. Interestingly, Torres-Mora et al., in one of the largest studies on MeS to date, have found that MeS tumours are significantly more aggressive than previously thought, with local recurrence in 35% of the cases and evidence of metastasis reaching 40% [5]. The group concludes that MeS is a distinctive malignant tumour, rather than benign neoplasm with occasionally unpredictable behaviour, proposing its reclassification as “malignant melanotic schwannian tumour”.

The comprehensive literature review conducted here, reveals that more than half of the cases (51.4%) are reported to have local or distal metastasis or both, confirming the suspicion that MeS is an aggressive neoplasm with high malignant potential. The aforementioned case...
report, written in accordance to the SCARE 2018 guidelines [1], adds further value to the suspicion that MeS is an aggressive malignancy.

3. Conclusion

Melanotic schwannoma is a rare, aggressive and potentially malignant variant of schwannoma, one of the most commonly observed intradural extramedullary tumours in neurosurgical practice. A high degree of suspicion is required in the context of imaging findings demonstrating T1 hyperintensity and T2 hypointensity on MRI. Early screening with whole-body staging CT should be considered owing to the risk of distant metastases. The surgical strategy should be aimed at considering a gross total resection for optimal local control. This may necessitate intra-operative histological analysis by way of a frozen section to guide the extent of resection. Early follow-up and regular surveillance imaging are advisable. Further studies are required concerning adjuvant therapy in the treatment and whether this should be considered in all cases or only following a recurrence or metastatic disease.

Funding

Not applicable.

Availability of data and material

Table 1 includes all articles we used to conduct the literature review.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review

Not commissioned, externally peer reviewed.

Funding

No source of funding to declare.

Ethical approval

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Patients consent was obtain prior to writing the case report.

Author contribution

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

GS, TN, SA, have all contributed to the study design, data collection, data analysis, drafting and structuring the case report.

WA and PU, have contributed in the data collection, analysis and writing the paper.

Declaration of competing interest

No conflict of interest to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jamsu.2020.10.003.

References

[1] C. Santaguida, A.J. Sabbagh, M.C. Guiot, R.F. Del Maestro, Aggressive intramedullary melanotic schwannoma: case report, Neurosurgery 55 (6) (2004 Dec 1) E1430-E1434.
[2] W.G. Millar, A malignant melanotic tumour of ganglion cells arising from a neuregic sympathetic ganglion, J. Pathol. Bacteriol. 35 (3) (1925) 351-357.
[3] N. Ciftci, E. Dikicioglu, I. Meteoglu, Boyd S. Multiple melanotic schwannoma, Ann. Diagn. Pathol. 7 (4) (2003 Aug 1) 254-258.
[4] A. Ranjan, G. Chacko, S.M. Chandri, Intracerebellar melanotic schwannoma: A case report, Br. J. Neurosurg. 9 (5) (1995 Jan 1) 687-690.
[5] J. Torres-Mora, S. Dry, X. Li, S. Binder, M. A.L. Folpe, Malignant melanotic schwannian tumor: a clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of “melanotic schwannoma”, Am. J. Surg. Pathol. 36 (1) (2014 Jan 1) 94-105.
[6] A.V. Valtat-Decouvelaere, M. Wassef, G. Lot, M. Catala, M. Moussalan, N. Caruel, J. Mikol, Spinal melanotic schwannoma: a tumour with poor prognosis, Histopathology 35 (6) (1999 Dec) 556-566.
[7] D. Carter, Atlas of tumor pathology. Tumors of the peripheral nervous system, Am. J. Surg. Pathol. 24 (9) (2000 Sep 1) 1311-1312.
[8] L. De Cerchio, F. Contratti, M.F.R. Faioli, Dorsal dumb-bell melanotic schwannoma operated on by posterior and anterior approach: Case report and a review of the literature, Eur. Spine J. 15 (5) (2006 Oct 1) 664-669.
[9] J.M. Hoover, J.M. Bledsoe, C. Giannini, W.E. Kraus, Intramedullary melanotic schwannoma, Rare Tumors 4 (1) (2012 Jan 31) 7-10.
[10] H. Yokota, I. Isoke, M. Murakami, H. Kubosowa, T. Uno, Dumbbell-shaped nonpompomatous malignant melanotic schwannoma of the cervical spinal root, Spine J. 12 (4) (2012 Apr 1) e14-e17.
[11] T. Akiyoshi, Y. Ueda, K. Yanai, H. Yamaguchi, M. Kawamoto, K. Toyoda, T. Hayashi, J. Ohuchiba, Melanotic schwannoma of the pancreas: Report of a case, Surg. Today 34 (6) (2004 Jun 1) 550-553.
[12] H.Y. Zhang, G.H. Yang, J.H. Chen, B. Wei, Q. Ke, H. Guo, L. Ye, H. Bu, K. Yang, Y. H. Zhang, Clinicopathological, immunohistochemical, and ultrastructural study of 13 cases of melanotic schwannoma, Chin Med J (Engl). 118 (17) (2005 Sep 5) 1451-1461.
[13] J.A. Carney, Pompomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome, Am. J. Surg. Pathol. 14 (3) (1990 Mar) 206-222.
[14] D.G. Martin-Reay, M.C. Shattuck, F.W. Gurthrie Jr., Pompomatous melanotic schwannoma: an additional component of Carney’s complex: Report of a case, Am. J. Clin. Pathol. 95 (4) (1991 Apr 1) 484-489.
[15] C.A. Utiger, J.T. Headington, Pompomatous melanotic schwannoma: A new cutaneous marker for Carney’s complex, Arch. Dermatol. 129 (2) (1993 Feb 1) 202-204.
[16] D. Wilkes, D.A. McDermott, C.T. Basson, Clinical phenotypes and molecular genetic mechanisms of Carney complex, Lancet Oncol. 6 (7) (2005 Jul 1) 501-508.
[17] E. Marton, A. Feleti, E. Orvieto, P. Longatti, Dumbbell-shaped C2-pompomatous melanotic malignant schwannoma: Case report and review of the literature, J. Neurorad. Spine 6 (6) (2007 Jun 1) 591-599.
[18] M. Bendzros, H. Urbach, H.K. Wolf, J. Schramm, L. Solymosi, Magnetic resonance imaging of intraspinal melanotic schwannoma, Eur. Radiol. 8 (7) (1998 Sep 15) 1197.
[19] H.V. Küsters-Vandevelde, I.A. van Engen-van Grunsven, B. Küsters, M.R. van Dijk, Historical, clinicopathological, and genetic mechanisms of Carney complex, Lancet Oncol. 6 (7) (2005 Jul 1) E1430-E1434.
[20] H. Koga, S. Matsumoto, J. Manabe, T. Tanizawa, N. Kawaguchi, Definition of the tumour with special associations, including cardiac myxoma and the Cushing syndrome, Am. J. Surg. Pathol. 14 (3) (1990 Mar) 206-222.
[21] H. Cortes-Funes, The role of RANK-ligand inhibition in cancer: the story of denosumab, Oncol. 16 (2) (2011 Feb 1) 136-145.
[22] N.H. Segal, C.E. Ariyan, R.A. Gordon, K. Reed, M.M. Burke, Nivolumab plus denosumab, J. Clin. Neurosci. 14 (7) (2007 Jul 1) 676-678.
[23] D. Wilkes, D.A. McDermott, C.T. Basson, Clinical phenotypes and molecular genetic mechanisms of Carney complex, Lancet Oncol. 6 (7) (2005 Jul 1) 501-508.
[24] D. Carter, Atlas of tumor pathology: Tumors of the peripheral nervous system, Am. J. Surg. Pathol. 35 (6) (1999 Dec) 556-566.
[27] M.H. Faria, R.H. Doria-Netto, G.J. Osugue, L. de Souza Queiroz, F.E. Chaddad-Neto, Melanotic schwannoma of the cervical spine progressing with pulmonary metastatic Case report, Neurol. Med.-Chir. 53 (10) (2013) e2012-0283.

[28] R.L. Hamilton, K. Kuchelmiester, C. Lotz, R. Schönmyer, W. Schachenmayr, April 2004: woman in her early fifties with a cervical intraspinal and extraspinal MASSLESION, Brain Pathol. 14 (4) (2004 Oct) 453–454.

[29] R.M. Lowman, V.A. Livolsi, Pigmented (melanotic) schwannomas of the spinal canal, Cancer 46 (2) (1980) 391–397.

[30] H. Krichen, M.S. Daghfous, A. Mrabet, M. Douih, N. Slimane, M. Forest, Extended melanocytic tumor of the cervical spine. Apropos of a case of melanotic schwannoma, InAnnales de pathologie 13 (3) (1993) 184–187.

[31] W.L. McGavran III, G.W. Sypert, W.E. Ballinger, Melanotic schwannoma. Clinical and ultrastructural studies of three cases with evidence of intracellular melanin synthesis, Am. J. Surg. Pathol. 3 (1) (1979 Feb) 156–160.

[32] R.M. Lowman, V.A. Livolsi, Pigmented (melanotic) schwannomas of the spinal canal, Neurosurgery 11 (1 pt_1) (1982 Jul 1) 47–51.

[33] M.H. Faria, R.H. Doria-Netto, Melanotic schwannoma of the cervical canal, Cancer 46 (2) (1980) 391–397.

[34] R.G. Tawk, D. Tan, L. Mechtler, R.A. Fenstermaker, Melanotic schwannoma with drop metastases to the caudal spine and high expression of CD117 (c-kit), Journal of Neuro-oncology 68 (3) (2004 Jul 1) 249–254.

[35] N. Graziani, D. Gambarelli, J.M. Bartoli, G. Dechambenoit, S. Bellard, F. Grisoli, Extra-medullary intradural melanotic schwannoma: Apropos of a case of dorsal pigmented neurinoma. Review of the literature, Neurochirurgie 34 (3) (1988) 210–217.

[36] F. Paris, J. Cabanes, C. Munoz, L. Tamarit, Melanotic spinothoracic schwannoma, Neurosurgery. 2 (1) (1978 Jan 1) 47–51.

[37] M. Prieto-Rodríguez, A. Camañes, F. Cabanas, J. Araca, E. Velasquez, A. Sánchez-García, A. Sáez, J. Martínez, Melanotic schwannoma localized in the mediastinum: Diagnosis by fine-needle aspiration cytology, Diagn. Cytopathol. 19 (4) (1998 Oct) 298–302.

[38] A.K. Bagchi, S.K. Sarkar, D.P. Chakraborti, Melanotic spinal schwannoma, J. Clin. Pathol. 95 (4) (1991 Apr 1) 484–489.

[39] R. Buhl, H. Barth, H.H. Hugo, V.F. Mautner, H.M. Mehndorn, Intracranial and spinal melanotic schwannoma in the same patient, Journal of neuro-oncology 68 (3) (2004 Jul 1) 249–254.

[40] J.B. Gregorios, S.M. Chou, J. Bay, Melanotic schwannoma of the spinal cord, Neurol. Int. 2 (2011) 156–157.

[41] M. Parent, I. Brels-Noel, M. Lecomte-Houcke, C. Fontaine, A. Dupont, Melanotic schwannoma. Anatomico-clinical study of a case and review of the literature, Arch. Anat. Cytol. Pathol. 35 (2) (1987) 76–84.

[42] A. Bouzati, N. Kammoun, B. Zidi, F.H. Ben, H. Benzarri, A. Khelil, M.A. Ben, Melanotic schwannoma. A case with review of the literature, Arch. Anat. Cytol. Pathol. 42 (1) (1994) 46–53.

[43] M. Ludvikova, M. Michal, J. Marek, M. Syrnikov, Psammomatous melanotic schwannoma, Czech. Patol. 33 (4) (1997 Nov) 141–145.

[44] D.G. Martin-Reay, M.C. Shattuck, F.W. Guthrie Jr., Psammomatous melanotic schwannoma: An additional component of Carney’s complex: Report of a case, Am. J. Clin. Pathol. 95 (4) (1991 Apr 1) 484–489.

[45] L.C. Welling, V.M. Guirado, M. Tessari, A.R. Felix, C. Zanelatto, E.G. Figueiredo, M. A. Taricco, M.J. Teixeira, Spinal melanotic schwannomas, Arquivos de neuro-psiquiatria 70 (2) (2012 Feb) 156–157.

[46] J.M. Goromi, R.J. Grossman, J.A. Shields, J.J. Augsburger, P.M. Joseph, D. Delémeuse, Choroidal melanomas: Correlation of NMR spectroscopy and MR imaging, Radiology 158 (2) (1986 Feb) 443–445.

[47] I.C. Isiklar, N.E. Leeds, G.N. Fuller, A.J. Kumar, Intracranial metastatic melanoma: Correlation between MR imaging characteristics and melanin content, AJR. American journal of roentgenology. 165 (6) (1995 Dec) 1503–1512.

[48] A.B. Smith, E.J. Rushing, J.G. Smirniotopoulos, Pigmented lesions of the central nervous system: radiologic-pathologic correlation, Radiographics 29 (5) (2009 Sep) 1503–1524.

[49] Q.Y. Liu, A.M. Liu, H.G. Li, Y.B. Guan, Primary spinal melanoma of extramedullary origin: A report of three cases and systematic review of the literature, Spinal cord series and cases 1 (2015 Jul 9) 15003.

[50] C. Licata, S. Turazzi, R. Delfini, Bleeding cerebral neoplasms with symptomatic hematoma/Comment, J. Neurosurg. Sci. 47 (4) (2003 Dec 1) 201.

[51] M.F. Mafee, B. Linder, G.A. Peyman, B.G. Langer, K.H. Choi, V. Capek, Choroidal melanoma? Tumori Journal 81 (3) (1995 May) 208–212.

[52] E. Keskin, S. Ekmekci, O. Oztekin, G. Diniz, Melanotic schwannomas are rarely seen pigmented tumors with unpredictable prognosis and challenging diagnosis, in: Case Reports in Pathology, 2017.

[53] N. Azarpira, S. Torabineghad, M. Rakei, M.H. Bagheri, Cytologic findings in pigmented melanotic schwannoma, Acta Cytol. 53 (1) (2009) 113–115.

[54] I. Aprile, C.A. Scott, D. Cervesato, C.A. Beltrami, A. Meo, G. Fabris, Two rare lumbar tumours with unusual MRI characteristics, Neuroradiology 42 (6) (2000 Jun 1) 458–461.

[55] M. Khoo, I. Presney, R. Hargunani, R. Tirabosco, Melanotic schwannoma: an 11-year case series, Skeletal Radiol. 45 (1) (2016 Jan 1) 29–34.

[56] S.E. Choi, Y.J. Cha, J. Kim, H. Cha, J. Seo, S.U. Kuh, S.J. Kim, S.H. Kim, A rare case of aggressive melanotic schwannoma occurred in spinal nerve of a 59-year-old male, Journal of pathology and translational medicine 51 (3) (2017 Sep) 505–510.

[57] A. Bouzati, N. Kammoun, B. Zidi, F.H. Ben, H. Benzarri, A. Khelil, M.A. Ben, Melanotic schwannoma. A case with review of the literature, Arch. Anat. Cytol. Pathol. 42 (1) (1994) 46–53.

[58] M. Ludvikova, M. Michal, J. Marek, M. Syrnikov, Psammomatous melanotic schwannoma, Czech. Patol. 33 (4) (1997 Nov) 141–145.

[59] I. Aprile, C.A. Scott, D. Cervesato, C.A. Beltrami, A. Meo, G. Fabris, Two rare lumbar tumours with unusual MRI characteristics, Neuroradiology 42 (6) (2000 Jun 1) 458–461.

[60] R. M. Killeen, C.L. Davy, S.C. Bauserman, Melanocytic schwannoma. Cancer. 62 (1) (1988 Jul 1) 174–183.

[61] M. Parent, I. Brels-Noel, M. Lecomte-Houcke, C. Fontaine, A. Dupont, Melanotic schwannoma. Anatomico-clinical study of a case and review of the literature, Arch. Anat. Cytol. Pathol. 35 (2) (1987) 76–84.

[62] R. M. Killeen, C.L. Davy, S.C. Bauserman, Melanocytic schwannoma. Cancer. 62 (1) (1988 Jul 1) 174–183.

[63] M. Parent, I. Brels-Noel, M. Lecomte-Houcke, C. Fontaine, A. Dupont, Melanotic schwannoma. Anatomico-clinical study of a case and review of the literature, Arch. Anat. Cytol. Pathol. 35 (2) (1987) 76–84.